Response rates in patients with newly diagnosed chronic phase chronic myeloid leukemia (CML).
| Response . | IM + Low-dose Ara-C34 . | IM + High-dose Ara-C35 . | IM + Pegylated IFN36 . | High-dose Imatinib37 . | Standard-dose Imatinib2 . |
|---|---|---|---|---|---|
| * At 18 months of follow-up. | |||||
| Abbreviations: IM, imatinib; CHR, complete hematologic response; MCR, major cytogenetic response; CCR, complete cytogenetic response; MMR, major molecular response; CMR, complete molecular response. | |||||
| Number of patients | 30 | 127 | 76 | 114 | 553 |
| Follow-up (months) | 12 | 18 | 12 | 12 | 18 |
| CHR (%) | 100 | NR | 97 | 98 | 96 |
| MCR (%) | 83 | 83 | 83 | 96* | 87 |
| CCR (%) | 70 | 67 | 70 | 95 | 76 |
| MMR (%) | NR | 51 | 47 | 60 | 39 |
| CMR (%) | 2/15 | 28 | 14 | 26 | 4 |
| Grade 3/4 neutropenia (%) | 27 | NR | 63 | 36 | 14 |
| Grade 3/4 thrombocytopenia (%) | 37 | NR | 28 | 25 | 8 |
| Response . | IM + Low-dose Ara-C34 . | IM + High-dose Ara-C35 . | IM + Pegylated IFN36 . | High-dose Imatinib37 . | Standard-dose Imatinib2 . |
|---|---|---|---|---|---|
| * At 18 months of follow-up. | |||||
| Abbreviations: IM, imatinib; CHR, complete hematologic response; MCR, major cytogenetic response; CCR, complete cytogenetic response; MMR, major molecular response; CMR, complete molecular response. | |||||
| Number of patients | 30 | 127 | 76 | 114 | 553 |
| Follow-up (months) | 12 | 18 | 12 | 12 | 18 |
| CHR (%) | 100 | NR | 97 | 98 | 96 |
| MCR (%) | 83 | 83 | 83 | 96* | 87 |
| CCR (%) | 70 | 67 | 70 | 95 | 76 |
| MMR (%) | NR | 51 | 47 | 60 | 39 |
| CMR (%) | 2/15 | 28 | 14 | 26 | 4 |
| Grade 3/4 neutropenia (%) | 27 | NR | 63 | 36 | 14 |
| Grade 3/4 thrombocytopenia (%) | 37 | NR | 28 | 25 | 8 |